Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
Recruiting now · Phase 1
Conditions studied: Malignant Neoplasm
In brief
Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors. The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.
Key facts
- Study ID
- NCT07600749
- Run by
- Merck Sharp & Dohme LLC
- People needed
- 120
- Starts
- 2026-06-18
- Expected to finish
- 2029-10-04
- Last updated by the study team
- 2026-08-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Has a histologically or cytologically confirmed diagnosis of 1 of the following unresectable (locally advanced) and/or advanced (metastatic) solid tumors:
- Colorectal carcinoma (CRC)
- Renal cell carcinoma (RCC) that contains a clear cell component (with or without sarcomatoid and/or rhabdoid features)
- Nonsquamous non-small cell lung cancer (NSCLC)
- Biliary tract cancer (BTC) (intra-or extrahepatic cholangiocarcinoma (CCA)) or gallbladder cancer (GBC)
- Has measurable disease by Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1)
- Has adequate organ function
- Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on stable antiretroviral therapy (ART) for at least 4 weeks
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load
- Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
You may not qualify if…
- Has gastrointestinal malabsorption, a surgical procedure or a condition that could affect the absorption of the study drug
- Has a history of clinically significant cardiac, cardiovascular and/or cerebrovascular disease
- Has a serious nonhealing wound, ulcer, or bone fracture
- Has an active infection(s) requiring systemic therapy
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 2 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has a history of stem cell/solid organ transplant
- Has not adequately recovered from major surgery
Where it is running
- NEXT Oncology ( Site 0151) — San Antonio, Texas, United States (enrolling)
- Rambam Health Care Campus ( Site 0051) — Haifa, Israel (enrolling)
- Rabin Medical Center ( Site 0053) — Petah Tikva, Israel (enrolling)
- National Cancer Center Hospital ( Site 0201) — Chūō, Tokyo, Japan (enrolling)
- Cantonal Hospital St.Gallen ( Site 0101) — Sankt Gallen, Canton of St. Gallen, Switzerland (enrolling)
- Ospedale Regionale Bellinzona e Valli ( Site 0104) — Bellinzona, Canton Ticino, Switzerland (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.